申请人:Rigel Pharmaceuticals, Inc.
公开号:US20160257681A1
公开(公告)日:2016-09-08
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
本公开涉及一类化合物,其可用作蛋白激酶C(PKC)的抑制剂,因此可用于治疗通过PKC活性介导或维持的各种疾病和障碍。本公开还涉及包含这些化合物的制药组合物,使用这些化合物治疗各种疾病和障碍的方法,制备这些化合物和在这些过程中有用的中间体的方法。